Angle plc has announced a technological advancement that could extend the capability of its Parsortix diagnostic to treat cancer patients. The company’s noninvasive test captures and counts rare circulating tumor cells, or CTCs, from patients’ blood. A new process Angle has developed for recovering captured cells from the Parsortix cassette itself will enable analysis by a range of molecular techniques. The breakthrough holds the possibility of new diagnostic, prognostic, and...
Circulating tumor cells isolated using a new microfluidic device, then expanded in culture. Image source: The Wyss Institute for Biologically Inspired Engineering at Harvard University
A research collaboration between the Wyss Institute for Biologically Inspired Engineering at Harvard University and Children’s Hospital Boston has created a microfluidic device that can harvest rare circulating tumor cells (CTCs) from blood to enable their expansion in culture for analysis....
